Page 181 - CW E-Magazine (5-12-2023)

CPHI Barcelona 2023

SK Pharmteco showcases extensive APIs and cell &

gene therapy capabilities

SK Pharmteco, the South Korean SK pharmteco recently acquired a tinuous manufacturing of APIs earned
CDMO with expertise in small mole- controlling interest. recognition as a finalist in the ‘Accelera-
cule APIs and biopharmaceuticals, ting Innovation’ category at this year’s
presented its wide-ranging capabilities Besides presenting its global sup- CPHI Pharma Awards.
at the event. Representatives of the ply chain that spans across the US,
company and from its subsidiaries, Europe, and Asia, the company introduced SK pharmteco is a subsidiary of SK
including AMPAC Fine Chemicals, SK its end-to-end services for CGT, along Inc., the investment company for SK
biotek Ireland, Yposkesi and Center for with its continuous flow process manu- Group, South Korea’s second-largest
Breakthrough Medicines (CBM), atten- facturing technology for small mole- conglomerate, and has 13 offices and
ded the event. CBM is a US cell and cule APIs. SK pharmteco’s modular manufacturing facilities across the US,
gene therapy (CGT) CDMO in which platform for the rapid and flexible con- Europe, and Korea.
MOLECULES TO MEDICINES

ThermoFisher Scientific showcases integrated

offering for pharma value chain

US-headquartered conglomerate, Director, Global Head of Technical &
ThermoFisher Scientific, showcased Scientific Affairs, ThermoFisher Scien-
its wide range of offering helping the tific. “At CPHI, we continue to solidify
pharma and biotech sectors in accelerating our relationships with our current part-
research, solving analytical challenges, ners and look to build new partnerships
increasing productivity in laboratories, to develop medications and therapies
and in quest for novel therapies right or to bring these therapies faster to
from early development & clinical patients,” he added.
trials to scalable manufacturing and
integrated sourcing. Speaking about the key defining
trends in the global pharma industry
“ThermoFisher has been support- and ThermoFisher’s strategy to align
ing the pharma partners from drug with it, he said, “We continue to see
substance development, clinical and that small molecules are here to stay,
commercial manufacturing, whether it’s but there is huge interest in biologics.
small molecule or large molecule, be- Fisher now, as a clinical research There is more interest in advanced
sides clinical trial services, clinical group. With these capabilities, we are therapies such as viral vectors, cell and
packaging, labelling, distribution, etc. providing end-to-end services to our gene therapy, plasmids, mRNAs, etc.
We also have acquired the former PPD, pharma partners for any types of mole- We have invested in the last several
which is a clinical research arm. It’s a cules coming out of drug discovery,” years in all these modalities to support
separate business entity within Thermo- informed Dr. Anil Kane, Executive our partners”.
Chemical Weekly | Import-Export Data | Market Surveys
Directories | Business Forums | Expositions
The only organisation in India catering exclusively to the needs of the entire chemical industry
Contact:
SEVAK PUBLICATIONS PVT. LTD.
602-B, Godrej Coliseum, K.J. Somaiya Hospital Road, Behind Everard Nagar, Sion (E), Mumbai 400 022.
Phone: +91-22-24044471 / 72; Email: admin@chemicalweekly.com

Chemical Weekly December 5, 2023 181

Contents Index to Advertisers Index to Products Advertised